arginyl-glycyl-aspartic acid and Rhabdomyosarcoma 2

arginyl-glycyl-aspartic acid has been researched along with Rhabdomyosarcoma 2 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Rengaswamy, V; Rössler, J; Süss, R; Zimmer, D	1

Other Studies

1 other study(ies) available for arginyl-glycyl-aspartic acid and Rhabdomyosarcoma 2

Article	Year
RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. Journal of controlled release : official journal of the Controlled Release Society, 2016, 08-10, Volume: 235 Topics: Animals; Apoptosis; Cell Line, Tumor; Female; Forkhead Box Protein O1; Green Fluorescent Proteins; Humans; Liposomes; Mice, SCID; Nanoparticles; Oligopeptides; PAX3 Transcription Factor; Protamines; Rhabdomyosarcoma, Alveolar; RNA, Messenger; RNA, Small Interfering; Tumor Burden	2016

Article

Year

RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.

Journal of controlled release : official journal of the Controlled Release Society, 2016, 08-10, Volume: 235

Topics: Animals; Apoptosis; Cell Line, Tumor; Female; Forkhead Box Protein O1; Green Fluorescent Proteins; Humans; Liposomes; Mice, SCID; Nanoparticles; Oligopeptides; PAX3 Transcription Factor; Protamines; Rhabdomyosarcoma, Alveolar; RNA, Messenger; RNA, Small Interfering; Tumor Burden

2016